ArticleOphthalmology2019
Assessment of Vitreous Structure and Visual Function after Neodymium:Yttrium-Aluminum-Garnet Laser Vitreolysis.
Article in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Curcumin-Based Supplement for Vitreous Floaters Post-Nd:YAG Capsulotomy: A Pilot Study.Vision (Basel, Switzerland) · 2025Article
- Clinical Management of Vision Degrading Myodesopsia from Vitreous Floaters: Observation vs. Limited Refractive Vitrectomy.Ophthalmology. Retina · 2025Article
- Vitreous Floaters Functional Questionnaire for Vision-Degrading Myodesopsia From Vitreous Floaters.JAMA ophthalmology · 2025Article
- Light Scattering by Vitreous of Humans With Vision Degrading Myodesopsia From Floaters.Investigative ophthalmology & visual science · 2024Article
- No side effects on rabbit retina or vitreous microenvironment by nd:YAG laser vitreolysis.BMC ophthalmology · 2024Article
- Article
- Vision degrading myodesopsia assessed with optos ultra-widefield scanning laser ophthalmoscope.BMC ophthalmology · 2023Article
- Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis.International ophthalmology · 2023Article
- Machine Independence of Ultrasound-Based Quantification of Vitreous Echodensities.Translational vision science & technology · 2023Article
- Spontaneous remission of vision degrading myodesopsia of posterior vitreous detachment type.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Design of a Functional Eye Dressing for Treatment of the Vitreous Floater.Journal of personalized medicine · 2022Article
- Visualization and Grading of Vitreous Floaters Using Dynamic Ultra-Widefield Infrared Confocal Scanning Laser Ophthalmoscopy: A Pilot Study.Journal of clinical medicine · 2022Article
- The effectiveness of laser vitreolysis for vitreous floaters in posterior vitreous detachment.Indian journal of ophthalmology · 2022Article
- The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD.Ophthalmology and therapy · 2022Article
- Exploration of the Visual Function after the Implantation of Continuous Visual Range Human Cocrystal Micromonocular Vision in Both Eyes of the Patient.Journal of healthcare engineering · 2022Article
- Spherical submicron YAG:Ce particles with controllable particle outer diameters and crystallite sizes and their photoluminescence properties.RSC advances · 2021Article
- Spontaneous posterior vitreous detachment: A glance at the current literature.World journal of experimental medicine · 2021Review
- [Advertising or information in ophthalmology? : Scientific evaluation of a YouTube sample].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Effect of Applying Binocular Visual Training after Slanted Lateral Rectus Recession on Orthophoric Rate and Binocular Visual Function Recovery on Patients with Convergence Insufficiency-Type Intermittent Exotropia.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Vitreous Antioxidants, Degeneration, and Vitreo-Retinopathy: Exploring the Links.Antioxidants (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
purposeNeodymium:yttrium-aluminum-garnet (Nd:YAG) laser treatment is performed on vitreous floaters, but studies of structural and functional effects with objective outcome measures are lacking. This study evaluated Nd:YAG laser effects by comparing participants with vitreous floaters who previously underwent laser treatment with untreated control participants and healthy persons without vitreous floaters using quantitative ultrasonography to evaluate vitreous structure and by measuring visual acuity and contrast sensitivity function to assess vision.
designRetrospective, comparative study.
participantsOne eye was enrolled for each of 132 participants: 35 control participants without vitreous floaters, 59 participants with untreated vitreous floaters, and 38 participants with vitreous floaters previously Nd:YAG-treated. Of these, 25 were dissatisfied and sought vitrectomy; 13 were satisfied with observation.
methodsThe 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) to assess participant visual well-being, quantitative ultrasonography (QUS) to measure vitreous echodensity, and best-corrected visual acuity (BCVA) and contrast sensitivity function (CSF) to evaluate vision.
main outcome measuresResults of NEI-VFQ-39, QUS, BCVA, and CSF.
resultsCompared with control participants without vitreous floaters, participants with untreated vitreous floaters showed worse NEI-VFQ-39 results, 57% greater vitreous echodensity, and significant (130%) CSF degradation (P < 0.001 for each). Compared with untreated eyes with vitreous floaters, Nd:YAG-treated eyes had 23% less vitreous echodensity (P < 0.001), but no differences in NEI-VFQ-39 (P = 0.51), BCVA (P = 0.42), and CSF (P = 0.17) results. Of 38 participants with vitreous floaters who previously were treated with Nd:YAG, 25 were dissatisfied and seeking vitrectomy, whereas 13 were satisfied with observation. Participants seeking vitrectomy showed 24% greater vitreous echodensity (P = 0.018) and 52% worse CSF (P = 0.006). Multivariate linear regression models confirmed these findings.
conclusionsAs a group, participants previously treated with Nd:YAG laser for bothersome vitreous floaters showed less dense vitreous, but similar visual function as untreated control participants with vitreous floaters. Because some treated eyes showed less dense vitreous and better visual function than those of untreated control participants, a prospective randomized study of Nd:YAG laser treatment of vitreous is warranted, using uniform laser treatment parameters and objective quantitative outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.